NCT07685808ClinicalTrials.gov
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity
בקצרה
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…
שלב 2דרושים 360 משתתפים22 אתריםמדינה אחת
קטגוריות
רשום במרשם אחד
- ClinicalTrials.govNCT07685808פתיחת רשומה זו ב־ClinicalTrials.govסונכרן שלשום
מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.
מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.
מתעניינים במחקר הזה?
התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 360 participants (target), run at 22 sites.
How this score is built
- Enrolment25/40
360 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration6/10
Planned over about 18 months
- Sponsor scale9/10
Regeneron Pharmaceuticals has led 250 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
תקציר
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
מצבים רפואיים
- Overweight or Obesity
זכאות
| מין | הכול |
|---|---|
| גילאים | 18 Years – ללא מקסימום |
| מתנדבים בריאים | לא |
זכאות כפי שנכתבה במרשם
זכאות במשפטים פשוטים
הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.
תכנון המחקר
| סוג המחקר | התערבותי |
|---|---|
| שלב | שלב 2 |
| הקצאה | אקראי |
| מודל ההתערבות | PARALLEL |
| מטרה ראשית | TREATMENT |
| הסתרה | QUADRUPLE (4) |
| גיוס | דרושים 360 משתתפים |
נותן חסות ושותפים
- Regeneron Pharmaceuticals נותן חסות
זרועות והתערבויות
- Olatorepatide arm 1EXPERIMENTAL
- Olatorepatide arm 2EXPERIMENTAL
- Olatorepatide arm 3EXPERIMENTAL
- Olatorepatide arm 4EXPERIMENTAL
- Olatorepatide arm 5EXPERIMENTAL
- Matching Placebo arm 6ACTIVE_COMPARATOR
התערבויות
- תרופה Olatorepatide
Administered per the protocol
- תרופה Placebo
Administered per the protocol
מדדי תוצאה
מדד תוצאה ראשוני
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
מסגרת זמן Up to approximately 60 weeks
מדד תוצאה ראשוני
Severity of TEAEs
מסגרת זמן Up to approximately 60 weeks
מדד תוצאה ראשוני
Percent change in body weight
מסגרת זמן From baseline to week 52
מדד תוצאה משני
Olatorepatide concentrations
מסגרת זמן Up to approximately 60 weeks
מדד תוצאה משני
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
מסגרת זמן Up to approximately 52 weeks
מדד תוצאה משני
Magnitude of ADA to olatorepatide
מסגרת זמן Up to approximately 52 weeks
תאריכים
| תאריך התחלה | 28 ביולי 2026 (בפועל) |
|---|---|
| סיום ראשוני | 21 בינואר 2028 (משוער) |
| סיום | 21 בינואר 2028 (משוער) |
| פורסם לראשונה | 6 ביולי 2026 (בפועל) |
| עודכן לאחרונה | 18 בנובמבר 2026 |
| התוצאות פורסמו | לא צוין ברשומת המרשם |
| המצב אומת לאחרונה | נובמבר 2026 |
בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.
מיקומים
22 אתרים מגייסים
United States
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Flourish Research, Ravenswood Rheumatology | Chicago | Illinois | מגייס |
| Charter Research LLC - Chicago | Chicago | Illinois | מגייס |
| Alliance for Multispecialty Research (AMR) Clinical Miami | Doral | Florida | מגייס |
| AMR Clinical - Fort Myers | Fort Myers | Florida | מגייס |
| Tribe Clinical Research | Greenville | South Carolina | מגייס |
| AGA Clinical Trials | Hialeah | Florida | מגייס |
| Flourish Research, Nature Coast Clinical Research | Inverness | Florida | מגייס |
| Flourish Research, Jacksonville Center for Clinical Research | Jacksonville | Florida | מגייס |
| AMR Clinical - Lexington | Lexington | Kentucky | מגייס |
| K2 Medical Research Maitland LLC, Main Office | Maitland | Florida | מגייס |
| AMR Clinical - Mobile | Mobile | Alabama | מגייס |
| NYC Research Inc | New York | New York | מגייס |
| AMR Clinical - Chicago Oak Brook | Oak Brook | Illinois | מגייס |
| Velocity Clinical Research - Omaha | Omaha | Nebraska | מגייס |
| Rochester Clinical Research | Rochester | New York | מגייס |
| Flourish Research, Legacy Oaks Tower | San Antonio | Texas | מגייס |
| The IMA Group, IMA Clinical Research St. Petersburg | St. Petersburg | Florida | מגייס |
| Charter Research LLC - The Villages | The Villages | Florida | מגייס |
| Diablo Clinical Research - Flourish Research | Walnut Creek | California | מגייס |
| Chase Medical Research | Waterbury | Connecticut | מגייס |
| AMR Clinical Wichita | Wichita | Kansas | מגייס |
| Clinical Site Partners, LLC DBA Flourish Research | Winter Park | Florida | מגייס |
מסמכי המחקר
לא צורפו מסמכים ברשומת מרשם זו.
שינויים לאורך זמן
- 18 בנובמבר 2026
אתר נוסף
1 site added (22 total)
2122
- 13 באוקטובר 2026
אתר נוסף
3 sites added (21 total)
1821
- 29 בספטמבר 2026
אתר נוסף
13 sites added (18 total)
518
- 20 באוגוסט 2026
המצב השתנה
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 20 באוגוסט 2026
הגיוס נפתח
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 20 באוגוסט 2026
אתר נוסף
5 sites added (5 total)
05